Dr Lalchandani Labs (BOM:541299) Cash And Cash Equivalents : ₹22.92 Mil (As of Mar. 2024)

View and export this data going back to 2018. Start your Free Trial

What is Dr Lalchandani Labs Cash And Cash Equivalents?

Dr Lalchandani Labs's quarterly cash and cash equivalents declined from Mar. 2023 (₹31.02 Mil) to Sep. 2023 (₹24.08 Mil) but then stayed the same from Sep. 2023 (₹24.08 Mil) to Mar. 2024 (₹22.92 Mil).

Dr Lalchandani Labs's annual cash and cash equivalents declined from Mar. 2022 (₹35.33 Mil) to Mar. 2023 (₹31.02 Mil) and declined from Mar. 2023 (₹31.02 Mil) to Mar. 2024 (₹22.92 Mil).

Dr Lalchandani Labs Cash And Cash Equivalents Historical Data

The historical data trend for Dr Lalchandani Labs's Cash And Cash Equivalents can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Dr Lalchandani Labs Cash And Cash Equivalents Chart

Dr Lalchandani Labs Annual Data

Trend

Mar15

Mar16

Mar17

Mar18

Mar19

Mar20

Mar21

Mar22

Mar23

Mar24

Cash And Cash Equivalents

Get a 7-Day Free Trial

22.53

28.92

35.33

31.02

22.92

Dr Lalchandani Labs Semi-Annual Data
	Mar13	Mar14	Mar15	Mar16	Mar17	Sep17	Mar18	Sep18	Mar19	Sep19	Mar20	Sep20	Mar21	Sep21	Mar22	Sep22	Mar23	Sep23	Mar24
Cash And Cash Equivalents	Get a 7-Day Free Trial														35.33	35.64	31.02	24.08	22.92

Dr Lalchandani Labs Cash And Cash Equivalents Calculation

Cash and cash equivalents are the most liquid assets on the balance sheet. Cash equivalents are assets that are readily convertible into cash, such as money market holdings, short-term government bonds or Treasury bills, marketable securities and commercial paper.

Dr Lalchandani Labs (BOM:541299) Cash And Cash Equivalents Explanation

A high number means either:

1) The company has competitive advantage generating lots of cash

2) Just sold a business or bonds (not necessarily good)

A low stockpile of cash usually means poor to mediocre economics.

There are 3 ways to create large cash reserve.

1) Sell new bonds or equity to public

2) Sell business or asset

3) It has an ongoing business generating more cash than it burns (usually means durable competitive advantage)

When a company is suffering a short term problem, Buffett looks at cash or marketable securities to see whether it has the financial strength to ride it out.

Important: Lots of cash and marketable securities + little debt = good chance that the business will sail on through tough times.

Test to see what is creating cash by looking at past 7 yrs of balance sheets. This will reveal how the cash was created.

Be Aware

Depreciation estimates make the calculation of net income susceptible to management's accounting choices. These choices can be either overly aggressive or overly conservative.

Dr Lalchandani Labs Cash And Cash Equivalents Related Terms

Thank you for viewing the detailed overview of Dr Lalchandani Labs's Cash And Cash Equivalents provided by GuruFocus.com. Please click on the following links to see related term pages.

Dr Lalchandani Labs (BOM:541299) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Medical Diagnostics & Research » Dr Lalchandani Labs Ltd (BOM:541299) » Definitions » Cash And Cash Equivalents

Comparable Companies

Traded in Other Exchanges

N/A

Address

Greater Kailash, Part-1, M-20, Basement, South Delhi, New Delhi, IND, 110048

Website

https://www.lalchandanipathlab.com

Dr Lalchandani Labs Ltd engages in the business of running laboratories for carrying out pathological investigations of various branches of biochemistry, hematology, histopathology, microbiology, electrophoresis, immunology, virology, cytology, and other pathological and radiological investigations. It also offers Immunoassay, Immuno-Histochemistry, Molecular Pathology, DNA, and Genetic Testing. The company operates in two segments B2B sales and B2C sales, out of which the majority is from B2C sales. Revenue is generated from the sale of services.

Dr Lalchandani Labs (BOM:541299) Headlines

No Headlines